The work of Yost et al. in advanced human cancer showing that anti-PD-1 therapy mainly drives the replacement of pre-existing tumor-infiltrating CD8 T cell rather than reversing their exhausted status supports this statement [117]. The gene discussed is CD8A; the disease is cancer.